We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.53B
1-Year Est. Return 154.61%
This Fund
S&P 500
This Quarter Est. Return
+33.46%
1 Year Est. Return
+154.61%
3 Year Est. Return
+564.07%
5 Year Est. Return
+985.88%
10 Year Est. Return
–
AUM
$2.53B
AUM Growth
+$441M
Cap. Flow
+$174M
Cap. Flow %
6.85%
Top 10 Hldgs %
44.81%
Holding
120
New
30
Increased
23
Reduced
22
Closed
28

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$84.8M
2
AXSM icon
Axsome Therapeutics
AXSM
+$57.5M
3
EW icon
Edwards Lifesciences
EW
+$38.1M
4
ABT icon
Abbott
ABT
+$36.5M
5
UNH icon
UnitedHealth
UNH
+$31.5M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$49.3M
2
BTSG icon
BrightSpring Health Services
BTSG
+$38.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$30.6M
4
CNC icon
Centene
CNC
+$18.7M
5
FMS icon
Fresenius Medical Care
FMS
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.27%
2 Miscellaneous 3.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
26
Spyre Therapeutics
SYRE
$7.56B
$28.9M 1.14%
+325,000
New +$23.7M
NVO
27
Novo Nordisk
NVO
$171B
$28.8M 1.14%
+600,000
New +$25.8M
DFTX
28
Definium Therapeutics
DFTX
$4.86B
$25.9M 1.02%
550,000
+150,000
+38% +$3.71M
NBIX icon
29
Neurocrine Biosciences
NBIX
$14.1B
$25.3M 1%
150,000
– –
REGN icon
30
Regeneron Pharmaceuticals
REGN
$81.1B
$24.9M 0.99%
40,000
-45,000
-53% -$30.6M
IONS icon
31
CALL
Ionis Pharmaceuticals
IONS
$7.4B
$23.8M 0.94%
+300,000
New +$22.6M
BIIB icon
32
Biogen
BIIB
$33.6B
$21.6M 0.85%
100,000
+40,000
+67% +$7.65M
TVTX icon
33
Travere Therapeutics
TVTX
$5.6B
$21.3M 0.84%
+375,000
New +$16.6M
LNTH icon
34
Lantheus
LNTH
$6.51B
$21.1M 0.83%
190,000
+65,000
+52% +$6.06M
GKOS icon
35
Glaukos
GKOS
$9.11B
$21M 0.83%
150,000
-25,000
-14% -$3.16M
ORIC icon
36
Oric Pharmaceuticals
ORIC
$1.36B
$20.6M 0.81%
1,900,000
+500,000
+36% +$4.53M
BBIO icon
37
BridgeBio Pharma
BBIO
$12.8B
$20.5M 0.81%
275,000
– –
VRTX icon
38
Vertex Pharmaceuticals
VRTX
$133B
$19.9M 0.78%
40,000
– –
ALMS
39
Alumis Inc
ALMS
$919M
$19.7M 0.78%
700,000
-100,000
-13% -$2.33M
ELV icon
40
Elevance Health
ELV
$85.9B
$19.3M 0.76%
50,000
-25,000
-33% -$9.27M
CNC icon
41
Centene
CNC
$30.5B
$19.3M 0.76%
300,000
-350,000
-54% -$18.7M
ERAS icon
42
Erasca
ERAS
$4.98B
$18.3M 0.72%
1,000,000
+300,000
+43% +$4.29M
LLY icon
43
Eli Lilly
LLY
$1.05T
$18M 0.71%
15,000
– –
ARWR icon
44
Arrowhead Research
ARWR
$9.31B
$16.3M 0.64%
200,000
-100,000
-33% -$7.39M
NVST icon
45
Envista
NVST
$3.85B
$15.8M 0.62%
600,000
+250,000
+71% +$6.31M
MDT icon
46
Medtronic
MDT
$113B
$15.6M 0.62%
+200,000
New +$16.1M
WAT icon
47
Waters Corp
WAT
$42.6B
$15M 0.59%
+40,000
New +$13.6M
LIVN icon
48
LivaNova
LIVN
$4.22B
$14.8M 0.58%
180,000
+30,000
+20% +$2.12M
NVO
49
CALL
Novo Nordisk
NVO
$171B
$14.4M 0.57%
+300,000
New +$12.9M
FBRX
50
DELISTED
Forte Biosciences
FBRX
$14.3M 0.57%
675,000
+525,000
+350% +$12.4M
1
2
3 4 5

Similar funds

VWA
Visionary Wealth Advisors O'fallon, Illinois $2.53B AUM 24.4% 1-Year Est. Return
PVI
Pine Valley Investments Marlton, New Jersey $2.53B AUM 36.18% 1-Year Est. Return
AIM
Acropolis Investment Management St. Louis, Missouri $2.54B AUM 18.96% 1-Year Est. Return
QT
Quantbot Technologies New York $2.54B AUM 22.25% 1-Year Est. Return
LMIM
Lockheed Martin Investment Management Bethesda, Maryland $2.53B AUM 37.62% 1-Year Est. Return
ST
Sageworth Trust Lancaster, Pennsylvania $2.54B AUM 23.56% 1-Year Est. Return
NSAM
North Star Asset Management Neenah, Wisconsin $2.54B AUM 17.62% 1-Year Est. Return
IFA
Index Fund Advisors Irvine, California $2.52B AUM 26.26% 1-Year Est. Return

Integral Health Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Integral Health Asset Management held 120 positions worth $2.53B, up 21% from $2.09B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Integral Health Asset Management deployed $174M of net new capital in Q2 2026, opening 30 new positions and adding to 23 existing holdings. Its largest new stake was Abbott: 400,000 shares worth $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was BrightSpring Health Services, an estimated $38.9M trimmed.

  • Integral Health Asset Management's largest Q2 2026 buy was Abbott: 400,000 shares worth $36.3M.
  • Integral Health Asset Management added most to CVS Health in Q2 2026, an estimated $84.8M increase.
  • Integral Health Asset Management's biggest Q2 2026 reduction was BrightSpring Health Services, cutting an estimated $38.9M.
  • Integral Health Asset Management fully exited AstraZeneca in Q2 2026, selling an estimated $49.3M.
  • Integral Health Asset Management's ten largest holdings make up 45% of its $2.53B portfolio in Q2 2026.
  • Integral Health Asset Management opened 30 new positions and closed 28 in Q2 2026.
  • Integral Health Asset Management's portfolio value rose 21% quarter-over-quarter to $2.53B.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.